Related Experiment Video

Updated: Dec 5, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.2K

The SUMO pathway in pancreatic cancer: insights and inhibition

Christian Schneeweis1, Zonera Hassan1, Markus Schick2

  • 1Medical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, 81675, München, Germany.

British Journal of Cancer
|October 19, 2020
PubMed

Insights

Developing novel pancreatic ductal adenocarcinoma (PDAC) therapies is crucial. This review explores how small ubiquitin-like modifiers (SUMO)ylation impacts PDAC, particularly aggressive subtypes, and discusses emerging SUMOylation inhibitors for targeted treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) lacks effective targeted therapies despite extensive research.
  • Posttranslational modifications (PTMs), such as SUMOylation, play critical roles in cancer cell survival and proliferation.
  • SUMOylation influences key cellular processes including transcription, DNA repair, and cell division.

Purpose of the Study:

  • To review the role of the SUMOylation pathway in pancreatic ductal adenocarcinoma (PDAC).
  • To highlight the specific connection between SUMOylation and aggressive PDAC subtypes with high MYC activity.
  • To discuss the potential of SUMOylation inhibitors as targeted therapies for PDAC.

Main Methods:

  • Literature review of SUMOylation functions in cancer biology.
  • Focus on studies investigating SUMOylation in pancreatic ductal adenocarcinoma.
  • Analysis of the link between SUMOylation, MYC activity, and PDAC aggressiveness.

Main Results:

  • SUMOylation is implicated in critical pathways supporting PDAC cell fitness and survival.
  • A specific association exists between SUMOylation and aggressive PDAC phenotypes characterized by high MYC expression.
  • SUMOylation inhibitors are under development, showing promise for precise PDAC treatment strategies.

Conclusions:

  • The SUMOylation pathway represents a significant target for novel pancreatic ductal adenocarcinoma therapies.
  • Targeting SUMOylation may offer a precise therapeutic approach, especially for aggressive PDAC subtypes.
  • Further research into SUMOylation inhibitors could lead to improved treatment outcomes for PDAC patients.

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.4K
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.0K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.0K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.0K